The major goal of the Neuropathology Core of the Rush ADCC is to facilitate research on normal aging, mild cognitive impairment, Alzheimer's disease and other dementias by collecting and then providing a diverse range of investigators a resource of optimally preserved, processed and stored biospecimens, and state-of the-art neuropathoiogic data and diagnoses, from clinically well-characterized older subjects. Over the past years, the Core has supported a diverse range of different studies including clinical-pathologic studies, studies of normal aging and mild cognitive impairment and studies linking risk factors to the neuropathology and neurobiology underlying normal aging, MCI, clinical AD and other dementias. In addition the core has distributed biospecimens to externally-funded investigators at Rush, at other NIA funded Alzheimer's disease centers, and other researchers across the country, and has facilitated the publication of numerous manuscripts in peer-reviewed journals. The Core will continue to facilitate these studies and publications by continuing to practice optimal autopsy and collection procedures to obtain optimal ante-mortem and postmortem specimens and continue to use the uniform, standard and flexible techniques for preservation, processing and storage that allow for diverse research studies. The core will implement and maintain a DNA bank for all living and deceased participants. The Core will continue to use state-of-the-art diagnostic assessments on brain tissue to diagnose Alzheimer's disease, cerebral infarcts, and Lewy body disease, and will expand assessments for novel markers of pathology including TDP-43 and FUS. Using modern data management systems the Neuropathology Core will index and store data and diagnoses making these readily available for external research. The Neuropathology Core will continue to distribute high quality specimens and neuropathoiogic data and diagnoses for externally funded investigators to facilitate and expand the scope of research on normal aging, MCI, Alzheimer's disease and other dementias.
The Neuropathology Core will continue to facilitate new and support on-going studies of normal aging, MCI, AD and dementia by providing optimal biospecimens and collecting state-of-the-art neuropathoiogic data and diagnoses.
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2016) Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr 65:231-8|
|Forrester, Sarah N; Gallo, Joseph J; Smith, Gwenn S et al. (2016) Patterns of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Risk of Dementia. Am J Geriatr Psychiatry 24:117-25|
|Wilson, Robert S; Rajan, Kumar B; Barnes, Lisa L et al. (2016) Factors related to racial differences in late-life level of cognitive function. Neuropsychology 30:517-24|
|Ibrahim-Verbaas, C A; Bressler, J; Debette, S et al. (2016) GWAS for executive function and processing speed suggests involvement of the CADM2 gene. Mol Psychiatry 21:189-97|
|John, Samantha E; Gurnani, Ashita S; Bussell, Cara et al. (2016) The effectiveness and unique contribution of neuropsychological tests and the Î´ latent phenotype in the differential diagnosis of dementia in the uniform data set. Neuropsychology 30:946-960|
|Mufson, Elliott J; Malek-Ahmadi, Michael; Snyder, Noelle et al. (2016) Braak stage and trajectory of cognitive decline in noncognitively impaired elders. Neurobiol Aging 43:101-10|
|Montine, Thomas J; Monsell, Sarah E; Beach, Thomas G et al. (2016) Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. Alzheimers Dement 12:164-9|
|Lim, Andrew S P; Bennett, David A; Buchman, Aron S (2016) Response to Letter Regarding Article, "Sleep Fragmentation, Cerebral Arteriolosclerosis, and Brain Infarct Pathology in Community-Dwelling Older People". Stroke 47:e175|
|Liu, Rui-Xuan; Huang, Cui; Bennett, David A et al. (2016) The characteristics of astrocyte on AÎ² clearance altered in Alzheimer's disease were reversed by anti-inflammatory agent (+)-2-(1-hydroxyl-4-oxocyclohexyl) ethyl caffeate. Am J Transl Res 8:4082-4094|
|Dodge, Hiroko H; Zhu, Jian; Woltjer, Randy et al. (2016) Risk of incident clinical diagnosis of Alzheimer's disease-type dementiaÂ attributable to pathology-confirmed vascular disease. Alzheimers Dement :|
Showing the most recent 10 out of 586 publications